Canature Health Technology Co., Ltd. (SHE:300272)
7.49
-0.24 (-3.10%)
Apr 30, 2026, 3:08 PM CST
SHE:300272 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 1,063 | 602.54 | 894.88 | 413.1 | 281.45 |
Trading Asset Securities | 50 | 190.03 | 0 | 0 | 0.57 |
Cash & Short-Term Investments | 1,113 | 792.57 | 894.88 | 413.1 | 282.02 |
Cash Growth | 40.47% | -11.43% | 116.63% | 46.48% | 58.79% |
Accounts Receivable | 237.55 | 238.48 | 226.06 | 241.47 | 250.36 |
Other Receivables | 14.55 | 15.9 | 20.45 | 9.25 | 140.65 |
Receivables | 252.09 | 254.38 | 246.51 | 250.71 | 391.01 |
Inventory | 299.65 | 253.99 | 248.72 | 322.24 | 292.68 |
Prepaid Expenses | - | - | - | - | 0.92 |
Other Current Assets | 41.95 | 27.77 | 21.49 | 16.57 | 18.99 |
Total Current Assets | 1,707 | 1,329 | 1,412 | 1,003 | 985.62 |
Property, Plant & Equipment | 742.31 | 427.76 | 377.92 | 383.61 | 298.76 |
Long-Term Investments | 863.11 | 870.51 | 895.11 | 609.42 | 506.56 |
Goodwill | 151.15 | 150.87 | 152.27 | 175.15 | 189.88 |
Other Intangible Assets | 105.48 | 87.97 | 97.56 | 105.38 | 115.21 |
Long-Term Accounts Receivable | - | 1.33 | 1.59 | 1.86 | 2.39 |
Long-Term Deferred Tax Assets | 47.16 | 38.5 | 32.91 | 35.74 | 18.34 |
Long-Term Deferred Charges | 32.28 | 24.06 | 8.29 | 7.66 | 11.21 |
Other Long-Term Assets | 26.38 | 26.63 | 20.96 | 14.52 | 4.89 |
Total Assets | 3,675 | 2,956 | 2,998 | 2,336 | 2,133 |
Accounts Payable | 220.97 | 202.12 | 205.09 | 156.13 | 229.29 |
Accrued Expenses | 74.73 | 103.9 | 95.61 | 90.61 | 80.37 |
Short-Term Debt | 962.37 | 574.84 | 702.66 | 448.79 | 262.1 |
Current Portion of Long-Term Debt | 184.65 | 45.43 | 1.01 | 6.49 | 2.99 |
Current Portion of Leases | - | 25.17 | 25.18 | 23.89 | 8.19 |
Current Income Taxes Payable | 15.87 | 6.13 | 9.33 | 14.76 | 11.5 |
Current Unearned Revenue | 62.04 | 36 | 27.99 | 55.88 | 40.66 |
Other Current Liabilities | 296.35 | 110.14 | 92.57 | 100.78 | 118.88 |
Total Current Liabilities | 1,817 | 1,104 | 1,159 | 897.33 | 753.99 |
Long-Term Debt | 183.34 | 249.75 | 182.29 | 2.81 | 7.88 |
Long-Term Leases | 58.02 | 52.23 | 39.37 | 82.11 | 33.17 |
Long-Term Unearned Revenue | 30.62 | 24.25 | 24.51 | 18.77 | 21.03 |
Long-Term Deferred Tax Liabilities | 78.75 | 75.91 | 77.59 | 79.36 | 58.47 |
Other Long-Term Liabilities | 143.66 | 139.37 | 143.88 | 137.1 | 6.1 |
Total Liabilities | 2,311 | 1,645 | 1,627 | 1,217 | 880.63 |
Common Stock | 611.47 | 577.22 | 577.17 | 577.17 | 577.17 |
Additional Paid-In Capital | 179.85 | 87.53 | 62.65 | 75.51 | 203.97 |
Retained Earnings | 456.66 | 517.89 | 590.09 | 513.81 | 477.26 |
Treasury Stock | - | -57.13 | -28.11 | -85.29 | -53.92 |
Comprehensive Income & Other | 12.88 | 97.21 | 96.97 | 9.6 | -2.06 |
Total Common Equity | 1,261 | 1,223 | 1,299 | 1,091 | 1,202 |
Minority Interest | 102.63 | 88.37 | 72.37 | 27.67 | 49.81 |
Shareholders' Equity | 1,363 | 1,311 | 1,371 | 1,118 | 1,252 |
Total Liabilities & Equity | 3,675 | 2,956 | 2,998 | 2,336 | 2,133 |
Total Debt | 1,388 | 947.42 | 950.5 | 564.09 | 314.32 |
Net Cash (Debt) | -275.09 | -154.85 | -55.62 | -150.99 | -32.3 |
Net Cash Per Share | -0.47 | -0.27 | -0.10 | -0.27 | -0.06 |
Filing Date Shares Outstanding | 610.73 | 565.07 | 565.02 | 561.7 | 567.17 |
Total Common Shares Outstanding | 610.73 | 565.07 | 572.07 | 561.7 | 567.17 |
Working Capital | -109.99 | 224.98 | 252.16 | 105.3 | 231.63 |
Book Value Per Share | 2.06 | 2.16 | 2.27 | 1.94 | 2.12 |
Tangible Book Value | 1,004 | 983.89 | 1,049 | 810.28 | 897.33 |
Tangible Book Value Per Share | 1.64 | 1.74 | 1.83 | 1.44 | 1.58 |
Buildings | - | 232.03 | 170.13 | 166.83 | 166.83 |
Machinery | - | 411.93 | 373.76 | 356.96 | 346.01 |
Construction In Progress | - | 48.46 | 82.9 | 50.09 | 3.2 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.